1 Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, (HMC), Doha, Qatar.
2 Departments of Pediatrics, University of Alexandria, Alexandria, Egypt.
3 Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy.
4 Pharmacists, Department of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar.
5 Nurse Research Scientist, Cancer Clinical Trials Unit, National Center for Cancer Care and Research, Hamad
Medical Corporation (HMC), Doha, Qatar.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Due to the chronic nature of chelation therapy and the adverse
consequences of iron overload, patient adherence to therapy is an
important issue. Jadenu® is a new oral formulation of deferasirox
(Exjade®) tablets for oral suspension. While Exjade® is a dispersible
tablet that must be mixed in liquid and taken on an empty stomach,
Jadenu ® can be taken in a single step, with or without a light meal,
simplifying administration for the treatment of patients with chronic
iron overload. This may significantly improve the compliance to
treatment of patients with β-thalassemia major (BMT). The aim of this
study was to evaluate the drug tolerability and the effects of
chelation therapy on serum ferritin concentration, liver iron
concentration (LIC) and biochemical profiles in patients with BMT and
Our study shows that short-term treatment with Jadenu® is safe but is
associated with a non-significant decrease in LIC and serum ferritin
levels. Therefore, there is an urgent need for adequately-powered and
high-quality trials to assess the clinical efficacy and the long- term
outcomes of new deferasirox formulation.
Patients and Methods
|Table 1. Biochemical data before versus after Jadenu® treatment in patients with β-thalassemia major.|
|Table 2. Liver iron content, serum ferritin and hormonal parameters in patients with β-thalassemia major before and after Jadenu ® treatment.|
|Figure 1. Linear correlation between liver iron content and serum ferritin level in patients with β-thalassemia major.|